{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T09:30:54Z","timestamp":1763458254669,"version":"3.33.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.msard.2023.104876","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T01:19:34Z","timestamp":1688519974000},"page":"104876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Effects of disease-modifying therapies on lipid parameters in patients with multiple sclerosis"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1457-4366","authenticated-orcid":false,"given":"Nizameddin","family":"Koca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meral","family":"Sefero\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.msard.2023.104876_bib0047","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106487","article-title":"High density lipoprotein stimulated migration of macrophages depends on the scavenger receptor class B, type I, PDZK1 and Akt1 and is blocked by sphingosine 1 phosphate receptor antagonists","volume":"9","author":"Al-Jarallah","year":"2014","journal-title":"PLoS One"},{"issue":"1 January","key":"10.1016\/j.msard.2023.104876_bib0027","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/gt.2016.76","article-title":"Interferon beta overexpression attenuates adipose tissue inflammation and high-fat diet-induced obesity and maintains glucose homeostasis","volume":"24","author":"Alsaggar","year":"2017","journal-title":"Gene Ther."},{"issue":"7 September","key":"10.1016\/j.msard.2023.104876_bib0030","first-page":"359","article-title":"[Modifications of the lipid metabolism induced by interferon beta in multiple sclerosis patients and its relationship with the disease activity]","volume":"19","author":"Ara","year":"2004","journal-title":"Neurologia"},{"issue":"3 June","key":"10.1016\/j.msard.2023.104876_bib0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/1028415031000115945","article-title":"Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis","volume":"6","author":"Besler","year":"2003","journal-title":"Nutr. Neurosci."},{"issue":"1 January","key":"10.1016\/j.msard.2023.104876_bib0041","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/acn3.676","article-title":"Dimethyl fumarate treatment induces lipid metabolism alterations that are linked to immunological changes","volume":"6","author":"Bhargava","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"4 October-Decembet","key":"10.1016\/j.msard.2023.104876_bib0013","article-title":"HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis","volume":"5","author":"Blumenfeld Kan","year":"2019","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"5 November","key":"10.1016\/j.msard.2023.104876_bib0045","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/j.1476-5381.2009.00451.x","article-title":"FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system","volume":"158","author":"Brinkmann","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"4 January","key":"10.1016\/j.msard.2023.104876_bib0024","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/CIRCULATIONAHA.104.475673","article-title":"Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets","volume":"115","author":"Brown","year":"2007","journal-title":"Circulation"},{"issue":"10 September","key":"10.1016\/j.msard.2023.104876_bib0033","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1177\/1352458518761185","article-title":"Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: a case report","volume":"24","author":"Camara-Lemarroy","year":"2018","journal-title":"Mult. Scler."},{"issue":"6376 February","key":"10.1016\/j.msard.2023.104876_bib0012","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1126\/science.aan4183","article-title":"Defective cholesterol clearance limits remyelination in the aged central nervous system","volume":"359","author":"Cantuti-Castelvetri","year":"2018","journal-title":"Science"},{"issue":"5 May","key":"10.1016\/j.msard.2023.104876_bib0040","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1172\/JCI72151","article-title":"Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE","volume":"124","author":"Chen","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"3 March","key":"10.1016\/j.msard.2023.104876_bib0022","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1194\/jlr.R009761","article-title":"Lipid metabolism in myelinating glial cells: lessons from human inherited disorders and mouse models","volume":"52","author":"Chrast","year":"2011","journal-title":"J. Lipid Res."},{"issue":"5 May","key":"10.1016\/j.msard.2023.104876_bib0043","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ana.22426","article-title":"Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis","volume":"69","author":"Cohen","year":"2011","journal-title":"Ann. Neurol."},{"issue":"1 January","key":"10.1016\/j.msard.2023.104876_bib0001","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1474-4422(13)70233-3","article-title":"Body fluid biomarkers in multiple sclerosis","volume":"13","author":"Comabella","year":"2014","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2023.104876_bib0053","first-page":"e413","article-title":"Biological therapies in rheumatic diseases","volume":"164","author":"Conti","year":"2013","journal-title":"Clin. Ter."},{"issue":"4 December","key":"10.1016\/j.msard.2023.104876_bib0021","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1086\/662453","article-title":"Multiple sclerosis is not a disease of the immune system","volume":"86","author":"Corthals","year":"2011","journal-title":"Q. Rev. Biol."},{"issue":"7 February","key":"10.1016\/j.msard.2023.104876_bib0032","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.medcli.2008.04.002","article-title":"[Lipid profile evolution during the first year of treatment with beta interferon in multiple sclerosis]","volume":"132","author":"Cuadrado-Godia","year":"2009","journal-title":"Med. Clin. (Barc)"},{"issue":"Suppl 1 January","key":"10.1016\/j.msard.2023.104876_bib0025","first-page":"S17","article-title":"Interferon-beta mechanisms of action in multiple sclerosis","volume":"74","author":"Dhib-Jalbut","year":"2010","journal-title":"Neurology"},{"issue":"November","key":"10.1016\/j.msard.2023.104876_bib0007","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.neulet.2018.10.030","article-title":"Cholesterol level correlate with disability score in patients with relapsing-remitting form of multiple sclerosis","volume":"687","author":"Durfinova","year":"2018","journal-title":"Neurosci. Lett."},{"issue":"3 May","key":"10.1016\/j.msard.2023.104876_bib0034","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1586\/17512433.2015.1019343","article-title":"Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases","volume":"8","author":"Fragoso","year":"2015","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"9 March","key":"10.1016\/j.msard.2023.104876_bib0016","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMra052130","article-title":"Multiple sclerosis\u2013the plaque and its pathogenesis","volume":"354","author":"Frohman","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"7 July","key":"10.1016\/j.msard.2023.104876_bib0006","doi-asserted-by":"crossref","first-page":"545","DOI":"10.12998\/wjcc.v3.i7.545","article-title":"Treatment strategies for multiple sclerosis: when to start, when to change, when to stop?","volume":"3","author":"Gajofatto","year":"2015","journal-title":"World J. Clin. Case."},{"issue":"5 May","key":"10.1016\/j.msard.2023.104876_bib0028","doi-asserted-by":"crossref","first-page":"e10484","DOI":"10.1371\/journal.pone.0010484","article-title":"Novel approaches to detect serum biomarkers for clinical response to interferon-beta treatment in multiple sclerosis","volume":"5","author":"Gandhi","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2023.104876_bib0029","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3389\/fphar.2015.00278","article-title":"Importance of Apolipoprotein A-I in Multiple Sclerosis","volume":"6","author":"Gardner","year":"2015","journal-title":"Front. Pharmacol."},{"issue":"1 January","key":"10.1016\/j.msard.2023.104876_bib0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00011-018-1185-0","article-title":"A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future","volume":"68","author":"Gholamzad","year":"2019","journal-title":"Inflamm. Res."},{"issue":"12 December","key":"10.1016\/j.msard.2023.104876_bib0057","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/art.24308","article-title":"Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy","volume":"59","author":"Gonzalez-Juanatey","year":"2008","journal-title":"Arthrit. Rheum."},{"year":"2016","series-title":"Then Bergh, F. Alterations of Serum Lipid Profile in Multiple Sclerosis Patients Treated With Fingolimod","author":"Haars","key":"10.1016\/j.msard.2023.104876_bib0052"},{"issue":"4 December","key":"10.1016\/j.msard.2023.104876_bib0050","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s11481-016-9697-2","article-title":"Effect of fingolimod-treatment on blood lipid profiles of multiple sclerosis patients","volume":"11","author":"Hovi","year":"2016","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"2 April-June","key":"10.1016\/j.msard.2023.104876_bib0049","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/039463201202500209","article-title":"Oral FTY720 administration induces immune tolerance and inhibits early development of atherosclerosis in apolipoprotein E-deficient mice","volume":"25","author":"Huang","year":"2012","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"July","key":"10.1016\/j.msard.2023.104876_bib0009","article-title":"Association of Obesity With Multiple Sclerosis Risk and Response to First-line Disease Modifying Drugs in Children","author":"Huppke","year":"2019","journal-title":"JAMA Neurol."},{"issue":"5 February","key":"10.1016\/j.msard.2023.104876_bib0042","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"6 June","key":"10.1016\/j.msard.2023.104876_bib0056","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10067-009-1095-1","article-title":"Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis","volume":"28","author":"Kerekes","year":"2009","journal-title":"Clin. Rheumatol."},{"issue":"6 June","key":"10.1016\/j.msard.2023.104876_bib0026","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11591110-000000000-00000","article-title":"The mechanism of action of interferon-beta in relapsing multiple sclerosis","volume":"25","author":"Kieseier","year":"2011","journal-title":"CNS Drug."},{"issue":"11 November","key":"10.1016\/j.msard.2023.104876_bib0051","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1161\/ATVBAHA.107.149476","article-title":"Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice","volume":"27","author":"Klingenberg","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"10 October","key":"10.1016\/j.msard.2023.104876_bib0036","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1002\/art.20498","article-title":"Life-threatening hypertriglyceridemia during leflunomide therapy in a patient with rheumatoid arthritis","volume":"50","author":"Laborde","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"Pt 3 March","key":"10.1016\/j.msard.2023.104876_bib0039","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/brain\/awq386","article-title":"Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway","volume":"134","author":"Linker","year":"2011","journal-title":"Brain"},{"issue":"6 June","key":"10.1016\/j.msard.2023.104876_bib0055","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/rheumatology\/kes006","article-title":"No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment","volume":"51","author":"Mathieu","year":"2012","journal-title":"Rheumatol. (Oxf.)"},{"issue":"5 August","key":"10.1016\/j.msard.2023.104876_bib0046","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1212\/WNL.0b013e3181ebdd64","article-title":"Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis","volume":"75","author":"Mehling","year":"2010","journal-title":"Neurology"},{"issue":"4\u20135 Apr-May","key":"10.1016\/j.msard.2023.104876_bib0003","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.autrev.2014.01.012","article-title":"Revised diagnostic criteria of multiple sclerosis","volume":"13","author":"Milo","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"6 June","key":"10.1016\/j.msard.2023.104876_bib0037","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/jhep.2003.50229","article-title":"Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values","volume":"37","author":"Mofrad","year":"2003","journal-title":"Hepatology"},{"issue":"19 November","key":"10.1016\/j.msard.2023.104876_bib0010","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1212\/WNL.0b013e3181c0d6e0","article-title":"Body size and risk of MS in two cohorts of US women","volume":"73","author":"Munger","year":"2009","journal-title":"Neurology"},{"issue":"June","key":"10.1016\/j.msard.2023.104876_bib0058","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.vph.2016.01.006","article-title":"Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis","volume":"81","author":"Naerr","year":"2016","journal-title":"Vascul Pharmacol."},{"issue":"2 April","key":"10.1016\/j.msard.2023.104876_bib0018","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1365-2990.1994.tb01174.x","article-title":"Low density lipoprotein uptake by macrophages in multiple sclerosis plaques: implications for pathogenesis","volume":"20","author":"Newcombe","year":"1994","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"4 January","key":"10.1016\/j.msard.2023.104876_bib0048","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1161\/CIRCULATIONAHA.106.641407","article-title":"FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice","volume":"115","author":"Nofer","year":"2007","journal-title":"Circulation"},{"issue":"8 August","key":"10.1016\/j.msard.2023.104876_bib0038","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40263-013-0080-z","article-title":"Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis","volume":"27","author":"Oh","year":"2013","journal-title":"CNS Drug."},{"issue":"12 December","key":"10.1016\/j.msard.2023.104876_bib0044","first-page":"2757","article-title":"Sphingosine 1-phosphate signal survival and mitogenesis are mediated by lipid-stereospecific binding of triacylglycerol-rich lipoproteins","volume":"60","author":"Pacheco","year":"2003","journal-title":"Cell. Mol. Life Sci."},{"issue":"5","key":"10.1016\/j.msard.2023.104876_bib0019","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1155\/2013\/567162","article-title":"New markers of early cardiovascular risk in multiple sclerosis patients: oxidized-LDL correlates with clinical staging","volume":"34","author":"Palavra","year":"2013","journal-title":"Dis. Mark."},{"issue":"4 April","key":"10.1016\/j.msard.2023.104876_bib0054","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/annrheumdis-2011-201228","article-title":"HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab","volume":"72","author":"Raterman","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"9 September","key":"10.1016\/j.msard.2023.104876_bib0017","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1089\/ars.2007.1663","article-title":"Role of redox regulation and lipid rafts in macrophages during Ox-LDL-mediated foam cell formation","volume":"9","author":"Schmitz","year":"2007","journal-title":"Antioxid. Redox. Signal."},{"issue":"12 October","key":"10.1016\/j.msard.2023.104876_bib0015","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.autrev.2010.07.016","article-title":"From endothelial dysfunction to atherosclerosis","volume":"9","author":"Sitia","year":"2010","journal-title":"Autoimmun. Rev."},{"issue":"2 March-April","key":"10.1016\/j.msard.2023.104876_bib0035","first-page":"382","article-title":"Severe hypertriglygeridemia in a rheumatoid arthritis patient treated with leflunomide","volume":"26","author":"Spanakis","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"issue":"2 February","key":"10.1016\/j.msard.2023.104876_bib0014","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nri3793","article-title":"Cholesterol, inflammation and innate immunity","volume":"15","author":"Tall","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"2 March-April","key":"10.1016\/j.msard.2023.104876_bib0002","first-page":"41","article-title":"Advances in the treatment of relapsing-remitting multiple sclerosis","volume":"37","author":"Tanasescu","year":"2014","journal-title":"Biomed. J."},{"issue":"Suppl 1 January","key":"10.1016\/j.msard.2023.104876_bib0004","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ene.12883","article-title":"Disease-modifying treatments for multiple sclerosis - a review of approved medications","volume":"23","author":"Torkildsen","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2023.104876_bib0011","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1136\/jnnp-2012-304740","article-title":"Lipid profiles are associated with lesion formation over 24\u2005months in interferon-\u03b2 treated patients following the first demyelinating event","volume":"84","author":"Weinstock-Guttman","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"December","key":"10.1016\/j.msard.2023.104876_bib0023","article-title":"Mechanisms of oxidative damage in multiple sclerosis and a cell therapy approach to treatment","author":"Witherick","year":"2011","journal-title":"Autoimmune Dis."},{"key":"10.1016\/j.msard.2023.104876_bib0031","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.1016\/j.jns.2013.07.1472","article-title":"Lipid profile in interferon and glatiramer acetate\/INS; using patients with multiple sclerosis","volume":"333","author":"Yildirim","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"January","key":"10.1016\/j.msard.2023.104876_bib0008","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.msard.2015.10.005","article-title":"Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes","volume":"5","author":"Zhornitsky","year":"2016","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823003772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823003772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T14:10:00Z","timestamp":1737641400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823003772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":58,"alternative-id":["S2211034823003772"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104876","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of disease-modifying therapies on lipid parameters in patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104876","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104876"}}